Jennison Associates LLC trimmed its stake in Progyny, Inc. (NASDAQ:PGNY – Free Report) by 6.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,528,790 shares of the company’s stock after selling 177,664 shares during the period. Jennison Associates LLC owned about 2.64% of Progyny worth $94,020,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in PGNY. RiverPark Advisors LLC raised its holdings in Progyny by 54.0% in the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock valued at $40,000 after acquiring an additional 374 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Progyny in the third quarter valued at $53,000. CWM LLC lifted its position in Progyny by 16.1% in the third quarter. CWM LLC now owns 3,490 shares of the company’s stock worth $119,000 after purchasing an additional 483 shares during the period. Cetera Trust Company N.A acquired a new stake in Progyny during the fourth quarter worth $183,000. Finally, Duality Advisers LP acquired a new stake in Progyny during the third quarter worth $202,000. Institutional investors own 94.93% of the company’s stock.
Progyny Stock Performance
Progyny stock opened at $33.06 on Tuesday. The business’s fifty day moving average is $36.51 and its two-hundred day moving average is $35.68. The firm has a market cap of $3.18 billion, a P/E ratio of 53.32, a P/E/G ratio of 1.35 and a beta of 1.48. Progyny, Inc. has a 52 week low of $29.44 and a 52 week high of $44.95.
Analysts Set New Price Targets
PGNY has been the subject of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $48.00 price objective on shares of Progyny in a research note on Wednesday, February 28th. KeyCorp dropped their target price on Progyny from $45.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, February 28th. Truist Financial restated a “buy” rating and set a $46.00 target price on shares of Progyny in a research report on Wednesday, April 17th. SVB Leerink started coverage on Progyny in a research report on Monday, February 26th. They issued an “outperform” rating and a $49.00 price target on the stock. Finally, Leerink Partnrs reissued an “outperform” rating on shares of Progyny in a report on Monday, February 26th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $48.30.
Check Out Our Latest Report on Progyny
Insider Transactions at Progyny
In related news, Chairman David J. Schlanger sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $37.52, for a total value of $37,520.00. Following the completion of the sale, the chairman now owns 83,631 shares of the company’s stock, valued at $3,137,835.12. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Chairman David J. Schlanger sold 1,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $37.52, for a total value of $37,520.00. Following the transaction, the chairman now owns 83,631 shares in the company, valued at $3,137,835.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, President Michael E. Sturmer sold 2,260 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $40.00, for a total value of $90,400.00. Following the sale, the president now directly owns 158,532 shares of the company’s stock, valued at $6,341,280. The disclosure for this sale can be found here. Over the last three months, insiders have sold 120,515 shares of company stock worth $4,570,131. Corporate insiders own 12.30% of the company’s stock.
About Progyny
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Further Reading
- Five stocks we like better than Progyny
- Dividend Payout Ratio Calculator
- Sherwin-William’s Win Over PPG Stock in The Construction Boom
- How to Invest in the FAANG Stocks
- Zscaler’s Potential Upside Continues to Explode
- Compound Interest and Why It Matters When Investing
- 3 A.I. Stocks to Watch Out For Not Named NVIDIA
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.